Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03082599 · ClinicalTrials.gov registry record · NA
Symfony Toric Intraocular Lens Visual Outcomes
A NA study of Astigmatism Bilateral and Cataract Bilateral, sponsored by Carolina Eyecare Physicians.
- Completed
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 4
- Study locations
NCT03082599: Completed NA study of Astigmatism Bilateral and Cataract Bilateral, sponsored by Carolina Eyecare Physicians.
NCT03082599 is a NA study of Astigmatism Bilateral and Cataract Bilateral that has completed, run by Carolina Eyecare Physicians. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03082599, a NA study of Astigmatism Bilateral and Cataract Bilateral, has completed, sponsored by Carolina Eyecare Physicians.
- COMPLETED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 4
- Study locations
Study Summary
In July 2016, the FDA approved an extended depth of focus (EDOF) IOL (Tecnis Symfony, Abbott Medical Optics) helping to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery. It is available in both a non-toric version and a toric version for patients with astigmatism. The difference between this lens and the multifocal (MIOL) counterpart is that the EDOF, similarly to a monofocal IOL, has one focal point (elongated in the EDOF) while the multifocals have 2 focal points; therefore, having less of a halo and glare problem. Pivotal trial results where Symfony was compared to a monofocal IOL showed similar uncorrected distance visual acuity (UCDVA), better intermediate (77% vs. 34% 20/25 uncorrected intermediate visual acuity - UCIVA) and near vision (Symfony patients were able to read two additional, progressively smaller lines compared to the monofocal IOL).A One potential disadvantage of the EDOF IOL compared to a MIOL is the visual performance at near.B One option to deal with this potential shortcoming is to set the non-dominant eye for a small residual myopic error (-0.50 D)C what is referred to as nano-vision or mini mono-vision.
Primary Outcome
Visual acuity with correction (glasses) measured at 40 cm.
Conditions Studied
Interventions
- DEVICE Presbyopia and astigmatism correcting intraocular lens
Study Locations (4)
Minnesota
- Associated Eye Care - Stillwater
New York
- Ophthalmic Consultants of Long Island - Garden City
South Carolina
- Carolina Eyecare Physicians, LLC - Mt. Pleasant
Texas
- Slade & Baker Vision Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-02-17 |
| Est. Completion | 2018-04-03 |
| Phase | NA |
What the finished NCT03082599 record still lists
NCT03082599 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Astigmatism Bilateral appearing as the primary indexed condition, and to 1 intervention - of which Presbyopia and astigmatism correcting intraocular lens is the first listed.
NCT03082599 reports a single indexed study location in Minnesota, New York, South Carolina.
Frequently Asked Questions
What is clinical trial NCT03082599 about?
NCT03082599 is a clinical study titled "Symfony Toric Intraocular Lens Visual Outcomes". In July 2016, the FDA approved an extended depth of focus (EDOF) IOL (Tecnis Symfony, Abbott Medical Optics) helping to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery. It is available in both a non-toric version and a toric...
What is the current status of trial NCT03082599?
This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2017-02-17. Estimated completion is 2018-04-03.
What conditions does trial NCT03082599 study?
This clinical trial studies the following conditions: Astigmatism Bilateral, Cataract Bilateral.
What interventions are being tested in trial NCT03082599?
The interventions under investigation include: Presbyopia and astigmatism correcting intraocular lens (DEVICE).
Who is sponsoring clinical trial NCT03082599?
This trial is sponsored by Carolina Eyecare Physicians, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03082599 being conducted?
This trial has 4 study locations across Minnesota, New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Astigmatism Bilateral
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03082599's enrollment target sits among peer trials
120 762nd of 2000 higher than 1,198 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI